【3886】Breast Cancer | HER2低表达与HER2零表达早期乳腺癌新辅助化疗后病理学完全缓解和预后差异 随着抗体药物偶联物(ADCs)的研发,HER2 低表达人群逐渐备受关注。目前,HER2 低表 达乳腺癌的生物学特征尚不十分明确,HER2 低表达与 HER2 ...
这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 low status in early-stage invasive lobular carcinoma of the breast: associate...
2023年，《Nature Communications》杂志发表了一篇题为《Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer》的文章，为我们提供了对这一问题深入的见解。研究方法 本研究旨在深入分析HER2低表达（HER2-low）和HER2-0（免疫组化[IHC] 0）乳腺癌的基因组特征，并探讨两者是否存在显著的分子差...
相关论文于当地时间8月22日在线发表于国际知名期刊《自然-通讯》（Nature Communications），题为“Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer”，这也是该研究在2022年圣安东尼奥乳腺癌大会（SABCS）入选亮点讨论后的正式见刊。邵志敏、江一舟团队论...
[18] Xu B, Ma F, Ouyang Q, et al. Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. 2018. ...
在过去 HER2靶向治疗成果的基础上,对这些新概念的研究和这些方法的使用将最终导致持续的进展。 参考文献:1.Sandra M. Swain, Mythili Shastry & Erika Hamilton Targeting HER2-positive breast cancer: advances and future directions Nature Reviews Drug Discovery(2022)...
[10]Diéras V, Deluche E, Lusque A,et al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY) . 2021 SABCS. PD8-02. [11]Home - ClinicalTrials.gov ...
[1]Nader-Marta G,Martins-Branco D,de Azambuja E.How we treat patients with metastatic HER2-positive breast cancer.ESMO Open.2022 Feb;7(1):100343. [2]Prat A,Guarneri V,ParéL,et al.A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer:a retr...
[1] VAN RAMSHORST MS, VAN DER VOORT A, VAN WERKHOVEN ED, et al. Neoadjuvant che-motherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial [J]. Lancet Oncol,2018.19(12)...
10.Slamon,D.et al.Adjuvant trastuzumab in HER2-positive breast cancer.N.Engl.J.Med.365,1273–1283(2011). 11.Moja,L.et al.Trastuzumab containing regimens for early breast cancer.Cochrane Database Syst.Rev.2012,CD006243(2012). 12.Nahta,R.&Esteva,F.J.Herceptin:mechanisms of action and resi...